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ABSTRACT
Relapsed acute leukemia after allogeneic transplantation has a poor prognosis and most reports have focused
on the role of second transplantations in relapsed patients. We report our single-institution experience on the
management of relapsed acute leukemia after allogeneic transplantation. We aimed to describe the outcome of
relapsed acute leukemia after allogeneic transplantation at our institution and investigate whether maneuvers
intended to augment donor T cell allogeneic reactivity were associated with durable graft-versus-leukemia
effects. We analyzed 310 patients with acute leukemia who received allogeneic hematopoietic progenitor cell
transplants from HLA-matched donors between 1982 and 2005 (229 with acute myelogenous leukemia, 81
with acute lymphoblastic leukemia). Mean post-transplant follow-up was 5 years (range, 0.5-22 years). Factors
associated with relapse incidence, therapy for relapse, response to treatment, and post-relapse survival were
assessed. One hundred of 310 patients (32%) with acute leukemia relapsed after transplantation, including 28
of 81 patients (35%) with acute lymphoblastic leukemia and 72 of 229 (31%) with acute myelogenous leukemia
at a median of 136 days after transplantation. Median post-relapse survival periods were 51 days for the 69
patients who received chemotherapy/supportive care, 84 days for 11 recipients of donor lymphocyte infusions,
303 days for 13 recipients of second transplants, and 442 days for 7 patients treated with interferon- and
granulocyte-macrophage colony-stimulating factor. A multivariable Cox regression analysis indicated that a
longer time to relapse after transplantation, peripheral blood as source of stem cells, and initial post-relapse
therapy with cytokines, donor lymphocyte infusions, or second transplants were associated with improved
post-relapse survival (P<.001,<.001, and .025). The outlook for patients with post-transplant relapse of acute
leukemia is extremely poor; currently, no single therapy consistently results in durable remissions. Our study
highlights the need for clinical trials in this area. Therapy with granulocyte-macrophage colony stimulating
factor and interferon--2b is promising and will be pursued in a prospective trial at our center.
© 2007 American Society for Blood and Marrow Transplantation
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sNTRODUCTION
Bone marrow or blood hematopoietic progenitor
ell transplantation (HPCT) remains the only poten-
ially curative therapy for patients with high-risk leuke-
ia; but relapse remains a signiﬁcant problem and is the
ajor cause of post-transplantation mortality. Patients
ith relapsed leukemia after HPCT have a very poor
rognosis and the optimal salvage therapy remains an
pen question. The existence of a graft-versus-leukemia
GVL) effect in the setting of clinical allogeneic trans-
lantation has been demonstrated for patients with acute m
16eukemia [1], and harnessing this effect in the post-
ransplantation relapse setting may improve post-relapse
utcomes. Although donor lymphocyte infusion (DLI)
ields complete remissions in 60%-86% of patients with
hronic myelogenous leukemia (CML) relapsed after
one marrow transplantation [2-6], the beneﬁt of DLI
or relapsed acute leukemia is limited, with overall sur-
ival rates of 15%-20% reported at 1 month to 3 years
4,7-9]. Second transplants are often considered to be the
tandard of care for patients with relapsed acute leuke-
ia after allogeneic transplantation and can provide du-
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Treatment of Post-transplant Relapse of Acute Leukemia 117able remissions in the small number of patients who are
ligible to receive second transplants. In a report to the
nternational Bone Marrow Transplant Registry (IB-
TR), Eapen et al [10] reported overall survivals of 41%
t 1 year and 28% at 5 years after second transplantation
or treatment of relapsed acute and chronic leukemia;
nd Meshinschi et al [11] reported a 56% 1-year survival
or 25 pediatric patients who received second transplants
or relapsed acute myelogenous leukemia (AML). Of
ote, younger patients and those with longer remission
ntervals had improved outcomes. In contrast, Radich et
l [12] reported a relapse rate of 76% and a disease-free
urvival rate of only 10% at 4 years for patients with
elapsed AML treated with second transplants [12]. Sec-
nd transplants are limited by availability of a donor, and
omorbidities related to the ﬁrst conditioning regimen
ay preclude administration of another course of high-
ose cytotoxic therapy. For patients who cannot tolerate
urther cytotoxic chemotherapy or second transplants,
mmune therapy aimed at inducing a GVL effect is a
easible option. Immunotherapy with interferon- alone
13,14] or with DLI [6] can effect remissions in patients
ith CML, but the role of cytokines in the management
f AML and acute lymphoblastic leukemia (ALL) relaps-
ng after allogeneic transplantation is poorly deﬁned and
imited to case reports [15-20] and small case series
21-24]. To describe the management of relapsed acute
eukemia after allogeneic transplantation and the fre-
uency of using different strategies to manage relapse at
ur institution, we performed a retrospective, single-
nstitution study of patients with acute leukemia who
eceived bone marrow or blood HPCT from HLA-
atched donors. We identiﬁed the patients who re-
apsed after transplantation and enumerated the different
alvage strategies applied and the clinical outcomes of
hose relapsed patients. Our goals were to describe the
verall incidence of relapse in our cohort, compare out-
omes for patients with ALL versus AML relapsed after
ransplantation, and compare outcomes for relapsed pa-
ients treated with salvage chemotherapy versus treat-
ents intended to induce an immune-mediated GVL
ffect. A secondary objective was to delineate any factors
hat may have affected the incidence of relapse in our
ohort of patients. We present long-term follow-up data
n the largest single-institution series of patients with
elapsed/refractory AML or ALL after allogeneic
PCT reported to date and demonstrate the feasibility
f inducing GVL effects in these patients.
ETHODS
atients and Data Collection
We reviewed 310 consecutive patients who under-
ent transplantation for acute leukemia at Emory
niversity between 1982 and February 2005. Dataegarding patient characteristics, source of stem cells tbone marrow versus blood HPCT), type of transplant
onor, disease status at diagnosis, cytogenetics at di-
gnosis, conditioning regimen, graft-versus-host dis-
ase (GVHD) prophylaxis, acute and chronic GVHD,
iagnosis of post-transplantation relapse, and type of
nitial salvage therapy were gathered after institutional
eview board approval of this retrospective analysis.
ll grafts were 5/6 or 6/6 HLA-antigen matched from
elated or unrelated donors. Recipients of cord blood
nd haploidentical transplants from related donors
ere not included in this study.
efinitions
Cytogenetic abnormalities were deﬁned as favor-
ble, unfavorable, poor, and unknown risk according
o the Southwest Oncology Group classiﬁcation for
ML [25,26] and as unfavorable or favorable for ALL
ccording to previous reports [25,27]. Relapse was
eﬁned as the post-transplantation presence of leuke-
ia cells detected by morphology or ﬂow cytometry
fter a complete remission (CR) had been achieved.
ersistent disease was deﬁned as post-transplantation
etection of leukemia without documentation of a
ost-transplantation CR. For acute promyelocytic
eukemia or Philadelphia chromosome-positive ALL,
he presence of the clonotypic molecular or cytoge-
etic abnormality was sufﬁcient to diagnose relapsed
r refractory leukemia. Response to post-relapse sal-
age therapy and post-relapse survival were evaluated
or each salvage modality, with CRs being hemato-
ogic, morphologic, or ﬂow cytometric clearance of
eukemic blasts from the blood or bone marrow. Post-
elapse survival was measured from the time of relapse
o time of death or censored at last contact date if
urvival status was not known.
ost-relapse Interventions
After the diagnosis of relapse was made, immuno-
uppression was discontinued in all patients, in the
bsence of signiﬁcant GVHD, and salvage therapy was
dministered as deemed appropriate by the treating
hysician. For patients whose leukemia relapsed after
mmunosuppression had been previously discontin-
ed, salvage therapy was given without delay. Types of
alvage therapies administered for treatment of re-
apsed disease were as follows: cytotoxic chemother-
py directed against leukemia cells; second transplants
hat consisted of administration of a graft containing
3 million CD34 cells from the original donor or
rom an unrelated donor after full myeloablative or
onmyeloablative conditioning; DLI, which was de-
ned as infusion of a dose of CD3 lymphocytes
range, 200 000 to 100 million/kg) containing 3
illion CD34 cells/kg with or without prior admin-
stration of reinduction chemotherapy; and cytokine
herapy, which consisted of treatment with interferon-
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M. L. Arellano et al.1183 million units subcutaneously 1-3 times per week)
ith or without concomitant granulocyte-macrophage
olony-stimulating factor (GM-CSF; 500 g subcuta-
eously 1-3 times per week). Cytokine treatment was
ontinued until toxicities or signs of GVHD devel-
ped or patients progressed. Chemotherapy/other sal-
age therapy included reinduction with regimens con-
aining any or a combination of cytarabine,
nthracycline, etoposide, or vincristine. Other drug
herapies including Gleevec for Philadelphia-chromo-
ome positive ALL (n  1), all-trans retinoic acid or
rsenic trioxide for acute promyelocytic leukemia
n  1) were included in the chemotherapy group.
tatistical Analysis
Kaplan-Meier estimates of overall post-transplan-
ation survival and survival after post-transplantation
elapse were calculated for patients with a diagnosis of
cute leukemia who underwent allogeneic HPCT.
og-rank statistics were used to compare survival
urves. Univariate analyses were performed using lo-
istic regression models. Variables deemed signiﬁcant
n univariate analysis were entered into Cox propor-
ional hazard models for multivariable analysis. Data
ere entered into the model using a forward condi-
ional method. Two-tailed P values 0.05 were con-
idered statistically signiﬁcant in all analyses. SPSS
oftware (SPSS Inc, Chicago, Ill) was used for all
nalyses.
ESULTS
The characteristics of 310 patients with ALL (81
atients, 26%) and AML (229 patients, 74%) who
eceived allogeneic transplants are listed in Table 1.
en comprised 54% of the population (168 of 310)
nd the median age of all patients was 36 years; 32%
f patients underwent transplantation with active re-
apsed or refractory leukemia, and 68% of patients
nderwent transplantation in CR. The conditioning
egimens consisted of cyclophosphamide plus total
ody irradiation or cyclophosphamide and busulfan
or fully myeloablative conditioning (93%) and ﬂu-
arabine-based reduced intensity conditioning (7%).
omplete data regarding incidence and grade/stage of
VHD were not available for the entire 310-patient
ohort, but limited data that included the presence or
bsence of GVHD were available for the 100 patients
ith relapsed/refractory disease.
Baseline characteristics of the relapsed and nonre-
apsed groups were similar, with the exception of dis-
ase status at transplantation, donor type, and cytoge-
etics at diagnosis.
elapse after Allogeneic Transplantation
In total, 72 of 229 patients (31%) with AML and
8 of 81 (35%) with ALL relapsed at a median of 136 days after transplantation. Cumulative incidences of
elapse were 26% for 211 patients who underwent
ransplantation in CR and 45% for 99 patients who
nderwent transplantation with relapsed/refractory
isease (Figure 1). Characteristics associated with a
igher likelihood of post-transplantation relapse on
nivariate analysis were: active disease at time of
ransplantation and unfavorable cytogenetics at diag-
osis of acute leukemia (P  .001 and .002, respec-
ively). Transplant procured from an unrelated donor
as associated with decreased risk of relapse (P 
019). All 3 risk factors remained signiﬁcantly associ-
ted with relapse on multivariable analysis (P  .001,
012, and .017 respectively). When AML and ALL
ases were analyzed separately, poor cytogenetic risk
as associated with higher risk of relapse among AML
ases only (multivariable P  .012), and unrelated
able 1. Patient Characteristics
Characteristic
All Patients
(n  310)
Relapsed
Patients
(n  100) P*
LL 81 (26%) 28 (28%) NS
ML 229 (74%) 72 (72%) NS
edian age 36 (13-68) 35 (15-60) NS
ale 168 (54%) 57 (57%) NS
ytogenetic risk
Favorable 49 (16%) 14 (14%)
Intermediate 87 (28%) 21 (21%)
Unfavorable 90 (29%) 42 (42%)
Unknown 84 (27%) 23 (23%) .002
isease status at
transplantation
Relapsed/refractory
leukemia 99 (32%) 45 (45%) <.001
tem cell source
BMT 213 (69%) 65 (65%)
Blood HPCT 97 (31%) 35 (35%) NS
VHD
Acute — 46 (46%) —
Chronic 29 (29%)
onor
Related 226 (73%) 83 (83%)
Unrelated 84 (27%) 17 (17%) 0.019
onditioning regimen†
TBI based 183 (59%) 59 (59%)
Busulfan/Cy 103 (33%) 35 (35%) NS
RIC 22 (7%) 6 (6%)
VHD prophylaxis
CSP based 119 (38%) 34 (34%)
Tacrolimus based 188 (61%) 64 (64%)
Other 4 (0.01%) 2 (2%) NS
LL indicates acute lymphoblastic leukemia; AML, acute myelog-
enous leukemia; BMT, bone marrow transplantation; HPCT,
hematopoietic progenitor cell transplantation; Cy, cyclophosph-
amide; GVHD, graft-versus-host disease; RIC, reduced inten-
sity conditioning; CSP, cyclosporine with or without methotrex-
ate; tacrolimus, tacrolimus with or without methotrexate; other,
T depletion/steroids/1 unknown.
Relapsed versus nonrelapsed patients.
Information not available for 2 patients.onor grafts were associated with decreased risk of
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Treatment of Post-transplant Relapse of Acute Leukemia 119elapse for ALL cases only (P  .033). Status of
eukemia at transplantation maintained its signiﬁcant
ssociation with relapse for patients with AML and
ith ALL (P  .001 for both). Factors not signiﬁ-
antly associated with post-transplantation relapse in-
luded age at transplantation, diagnosis (ALL versus
ML), conditioning regimen, and source of stem cells
peripheral blood versus bone marrow).
alvage Modalities to Treat Relapse
A summary of the various initial therapeutic ma-
euvers employed after the diagnosis of relapsed or
ersistent leukemia after allogeneic transplantation is
resented in Table 2. Immunosuppressive drug ther-
py was stopped in all patients upon the diagnosis of
elapse, before receiving any other therapy. Twenty-
ix patients received chemotherapy, radiation to ex-
ramedullary sites, antibody therapy, or tyrosine ki-
ase inhibitor as initial treatment of relapse, whereas
3 patients received supportive care without chemo-
herapy. Thirteen patients, who relapsed at a median
f 750 days after transplantation, received second
ransplants, 12 from the same donor and 1 from a
econd, matched unrelated donor. Eleven patients,
ho relapsed at a median of 89 days after transplan-
ation, received DLI containing a median of 5  107
onor T cells/kg; 4 of 11 patients received DLI con-
aining 1  108 CD3 cells/kg after induction che-
otherapy according to the schema developed by
ollins et al [28], and 7 of 11 patients received DLI
ithout preceding chemotherapy. Seven patients, who
igure 1. Relapse incidence according to disease status at trans-
lantation. Patients without (bottom curve) and with (top curve)
etectable leukemia at time of transplantation.
able 2. Initial Salvage Therapy for Relapsed Acute Leukemia
Therapy CR
GVHD afte
Relapse
hemo/supportive care (n  69) 5 (8%) 5 (8%)
econd transplant (n  13) 8 (62%) 7 (54%)
LI  chemotherapy (n  11) 5 (45%) 4 (36%)
ytokines (GM-CSF/IFN-á) (n  7) 5 (71%) 5 (71%)
R indicates complete remission; GVHD, graft-versus-host dis
macrophage colony stimulating factor/interferon-.elapsed at a median of 103 days after transplantation,
eceived GM-CSF/interferon- as the ﬁrst salvage
herapy. Second transplants were offered based on
onor availability; other therapies were administered
ased on physician preference. New-onset GVHD
eveloped in 33 patients with relapsed acute leukemia
nd was more prevalent among recipients of second
ransplants (7 of 13 patients), DLI (5 of 11 patients),
r cytokines (5 of 7 patients). Sixteen of the 69 pa-
ients treated with chemotherapy/supportive care de-
eloped GVHD after relapse. Development of
VHD after relapse was often, but not always, asso-
iated with a GVL effect. This effect was more evident
mong recipients of cytokines and second trans-
lants, where all patients who developed de novo
VHD had objective responses compared with only
responses among patients without post-relapse
VHD (P  .01). Interestingly, among patients
ith ALL, those who developed de novo GVHD
fter relapse lived longer than those who did not
evelop de novo GVHD (median survival, 6 versus
months, respectively, P  .013), but the same
ssociation was not observed among patients with
elapsed AML (P  .24).
urvival
Post-transplantation survival. The Kaplan-Meier
stimate for 3-year survival for all 310 patients was
2%. Factors signiﬁcantly associated with shorter
ost-transplantation survival after transplantation
ased on univariate analyses included active disease at
ime of transplantation, unfavorable cytogenetic risk
roup for patients with AML, older age, and bone
arrow as source of stem cells (P  .001, .001, .045,
nd .039, respectively), with all 3 factors remaining
igniﬁcant on multivariable analysis (P  .001, .045,
004, and .016, respectively). Kaplan-Meier estimates
f survival at 3 years were 43% for 145 patients who
nderwent transplantation in ﬁrst CR, 24% for 65
atients who underwent transplantation in second or
hird CR, and 15% for 99 patients who underwent
ransplantation with relapsed/refractory disease.
Survival after post-transplantation relapse. Median
urvival for the 100 patients with acute leukemia who
elapsed after allogeneic bone marrow or blood
PCT was 65 days. Median post-relapse survivals
ost-relapse Survival (d),
Median (Range)
Patients Alive (Days after Relapse
for Each Patient)
51 (0-1556) 3 (1556, 963, 832)
303 (40-3695) 1 (3695)
84 (15-882) 0
442 (149-1272) 3 (400, 1247, 1272)
LI, donor lymphocyte infusion; GM-CSF/IFN-á, granulocyte-r P
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M. L. Arellano et al.120ere 303 days for the 13 patients who received second
ransplants, 442 days for the 7 patients who received
M-CSF/interferon-, 84 days for the 11 patients
reated with DLI, 240 days for the 4 patients who
eceived reinduction chemotherapy followed by DLI
28], and 51 days for the 69 patients who received
hemotherapy/antibody therapy/radiation or sup-
ortive care. Despite the dismal outcome for our
ohort of patients with post-transplantation relapse
f acute leukemia, we observed that patients who
eceived salvage therapy with second transplants,
LI, or cytokines after withdrawal of immunosup-
ression lived longer than did patients who were
reated with chemo/supportive care alone after with-
rawal of immunosuppression (Figure 2). Post-relapse
urvival was similar for patients with AML and those
ith ALL (Figure 3). Among the 100 patients with
ost-transplant relapsed/refractory leukemia, only 7
atients remain alive and 1 has an unknown status. Of
he 7 cytokine-treated patients, 3 are alive, 1 without
vidence of disease on no immunosuppressive drugs
.5 years after relapse, another is in CR with chronic
xtensive GVHD 1 year after relapsing, and the other
atient has received intermittent cytokine therapy for
ersistent disease 3.5 years after initial relapse. Of the
3 patients who received second transplants, 1 re-
ains alive 10 years after relapse. Among the 11 pa-
ients who received DLI to treat relapse, there are no
ong-term survivors. Among the 69 patients who re-
eived chemotherapy or supportive care for relapse, 3
emain alive, 1 at 2.3 years after receiving all-trans
etinoic acid (ATRA) followed by arsenic trioxide for
elapsed acute promyelocytic leukemia, 1 at 4.3 years
fter receiving imatinib mesylate for relapsed Phila-
elphia chromosome-positive ALL, and the other pa-
igure 2. Post-relapse survival according to use of immune therapy,
xcluding withdrawal of immunosuppression alone. Dashed line
epresents immune therapy including second transplants, donor
ymphocyte infusion, or cytokines after withdrawal of immunosup-
ression. Solid line represents no immune therapy, except with-prawal of immunosuppression alone.ient achieved a CR after withdrawal of immunosup-
ression alone and has survived 2.7 years after relapse.
auses of Death for Patients Relapsing after
llogeneic Transplantation
The main cause of death for the group of patients
ith relapsed acute leukemia was leukemia in 74
80%), followed by infection/other causes in 15
16%). GVHD was the main cause of death in 4
atients (4%); 3 of those patients had received second
ransplant or DLI as salvage therapy. Of note, 1 of the
atients treated with cytokines died of sepsis during
teroid therapy for chronic extensive GVHD.
actors Associated with Survival after
ost-transplantation Relapse
Univariate analysis showed that a longer interval
etween ﬁrst transplantation and post-transplantation
elapse, use of any immune-based therapy (excluding
hemotherapy alone and withdrawal of immunosup-
ression alone), peripheral blood as source of stem
ells, and favorable cytogenetic risk group were asso-
iated with improved survival after relapse; and mul-
ivariable analysis showed that longer time to post-
ransplantation relapse, peripheral blood as source of
tem cells, and immune-based salvage therapies (sec-
nd transplants, DLI, cytokines) appeared to be asso-
iated with improved post-relapse survival (Table 3).
he following factors did not signiﬁcantly inﬂuence
urvival in the setting of post-transplantation relapse:
atient age, gender, donor type, or disease type (data
ot shown).
ISCUSSION
Relapse of acute leukemia after allogeneic trans-
igure 3. Survival after post-transplantation relapse according to
isease type. Acute lymphoblastic leukemia (solid line); acute my-
logenous leukemia (dashed line).lantation remains a signiﬁcant therapeutic challenge
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Treatment of Post-transplant Relapse of Acute Leukemia 121nd is the main cause of treatment failure after allo-
eneic transplantation. We have analyzed long-term
ollow-up data on patients who underwent transplan-
ation at a single institution to evaluate the incidence
f relapse in a consecutive series of patients treated at
single institution and to describe the strategies used
or treatment of post-transplantation relapse of acute
eukemia at our institution. The overall incidence of
2% relapse in our cohort is consistent with the pub-
ished 30%-60% incidence of relapse of acute leuke-
ia after allogeneic transplantation [29]. As expected,
higher incidence of relapse was observed among
atients who underwent transplantation with active
eukemia (45%) versus patients who underwent trans-
lantation in CR (26%, Figure 1). This is consistent
ith reported relapse rates of 45%-51% for patients
ho undergo transplantation with active disease
30-32]. Lower rates of relapse were seen among
ecipients of bone marrow or blood HPC transplants
btained from HLA-matched unrelated donors com-
ared with sibling donors, suggestive of an increased
VL effect associated with this donor cell source
33,34]. However, this beneﬁt in relapse was not offset
y improved survival for recipients of unrelated donor
ransplants, likely owing to higher treatment-related
ortality. Favorable cytogenetics were associated with
ower rates of relapse and improved survival after
ost-transplantation relapse [26,35].
Our study emphasizes the grim prognosis for pa-
ients with relapsed acute leukemia after allogeneic
ransplantation and highlights the need for more ef-
ective therapies. The nature of this nonrandomized,
etrospective analysis precludes any deﬁnitive conclu-
ion regarding the efﬁcacy or applicability of any par-
icular treatment for leukemia relapsed after alloge-
eic transplantation, but our observations suggest that
herapies aimed at enhancing the GVL effect of allo-
eneic transplantation, including second transplants,
M-CSF/interferon-, or DLI may be beneﬁcial for
mproving post-relapse survival. The use of chemo-
herapy alone to treat post-transplantation relapse of
cute leukemia appears to be largely ineffective. Sec-
nd transplants, which are often recommended as the
tandard of care for post-transplantation relapse of
cute leukemia, were administered to only a minority
able 3. Factors Associated with Death after Post-transplantation Relap
Factor Univaria
ime to relapse >136 d <.001
mmune-based salvage therapy <.001
eripheral blood as stem cell source <.001
avorable cytogenetic risk group .040
R indicates odds ratio; CI, conﬁdence interval.
Odds ratios 1 were associated with longer post-transplantation sf relapsed patients in our cohort (13 of 100 patients), and long-term (5-year) survival after second trans-
lants was only 11%. Historically, only 6%-20% of
elapsed patients actually receive second transplants
10,36]. The use of reduced intensity conditioning
egimens before second transplants may expand the
pplicability of second transplants in the relapse set-
ing, but long-term follow-up is limited [36,38-41].
he duration of remission after transplantation was an
mportant determinant of post-relapse outcome, as
as been shown in other series [10,37]. Despite the
bility of DLI to induce GVL effects in patients with
elapsed CML [6,42], the ability of DLI to produce
urable remissions for relapsed acute leukemia was
ot demonstrated in our cohort. We observed an
ncidence of CR of 45% in 11 patients who received
LI. However those remissions were short-lived and
here were no long-term survivors. Other investiga-
ors have reported similar results [28]. Collins et al
43] reported fewer responses to DLI for relapsed
LL and postulated that ALL may be less responsive
o the GVL effect. This lack of a GVL effect in ALL
s supported by the results of a review of 135 leukemic
atients who received DLI for treatment of post-
ransplantation relapse at 27 centers in the European
roup for Blood and Marrow Transplantation, where
o response to DLI alone was seen among 12 patients
ith ALL and a modest response of 29% in 17 pa-
ients with AML without durable remissions or long-
erm survival [4]. The addition of cytokine therapy to
LI may increase responses, but may also increase the
ncidence of life-threatening GVHD [24,44].
The use of interferon-/GM-CSF to induce a
raft versus leukemia effect may be promising as a
reatment strategy for patients with acute leukemia
elapsed after allogeneic transplantation. Administra-
ion of these cytokines produced complete remissions
n 5 of 7 (71%) treated patients, including 3 of 4
atients with relapsed AML and 2 of 3 patients with
elapsed ALL. Other investigators have also reported
n the feasibility of combining these 2 cytokines to
reat leukemia [45]. The mechanisms by which these
ytokines effect an antileukemia effect are not fully
nderstood, but hypotheses include (1) activation of
onor-derived dendritic cells that indirectly present
lloantigen and activate donor T cells; (2) differenti-
P
OR* (95% CI)Multivariable
<.001 0.35 (0.22-0.57)
.025 0.63 (0.38-0.98)
<.001 0.38 (0.24-0.61)
NS —
.se
tetion of residual host-type leukemic blasts into cells
w
a
d
d
4
i
b
b
e
t
t
t
l
a
t
R
1
1
1
1
1
1
1
1
1
1
2
2
2
2
2
2
2
M. L. Arellano et al.122ith dendritic cell properties that directly present
lloantigen and tumor-associated antigens to activate
onor T cells; and (3) direct or indirect activation of
onor T cells with or without natural killer cells [46-
8]. Although the ability of donor dendritic cells to
nhibit or augment alloreactivity of donor T cells has
een shown in preclinical models [49] and in clinical
one marrow transplantation [50], the ability of exog-
nously administered cytokines to cause differentia-
ion of leukemic blasts into antigen-presenting cells
hat activate cytotoxic donor T cells is a hypothesis
hat should be tested in a prospective clinical trial.
Our study demonstrates the poor outcome of re-
apsed acute leukemia after allogeneic transplantation
nd underlines the need for prospective studies of
herapies aimed at inducing durable GVL effects.
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